Trastuzumab

曲妥珠单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTrastuzumab
Drug Alias NameTrastuzumabum贺赛汀曲司珠单抗群司珠单抗Herceptin +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[28] 
Global Approved IndicationsStomach NeoplasmsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date1998/09/25
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[51] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesInstitut De Cancerologie Strasbourg EuropeAnshan Hospital, The First Affiliated Hospital Of China Medical UniversityIncepta Pharmaceuticals Ltd +[15] 
Inactive CompaniesDana-Farber Cancer InstituteInstitut CurieJules Bordet Institute +[13] 
Active IndicationsGastroesophageal Junction NeoplasmsEndometrial NeoplasmsStomach Neoplasms +[7] 
Inactive IndicationsMetastatic breast cancerSolid tumoursBreast Diseases +[21] 

Other Information

ATC CodeL01FD01L01XC03
Related LinksWikipediaDrugBankKEGG